King Pharma receives approval for new Bicillin facility

Bicillin L-A (penicillin G benzathine injectable suspension) is the first product available from this facility. Bicillin L-A, administered via deep intramuscular injection, has been used effectively for more than 60 years to cure syphilis and prevent sexual transmission.

“This modern facility demonstrates King’s commitment to the continued importance of treating and controlling infectious diseases,” stated Eric Bruce, chief technical operations officer, King Pharmaceuticals.

“With syphilis on the rise in major cities across the US, the new facility expands our production capacity to ensure continued availability of Bicillin L-A to healthcare providers and patients.”

Syphilis shows a significant increase in cities across the US, according to King. There were 8,852 new cases of primary and secondary syphilis reported at the end of 2006.